This Fox Chase professor participates in the Undergraduate Summer Research Fellowship.
Learn more about Research Volunteering.
Efrat Dotan, MD
- Request Appointment
- Clinical Locations
- About
- Education, Training & Credentials
- Patient Stories
- Research Profile
- Publications
Clinical Locations
Primary Location
Fox Chase Cancer Center
333 Cottman Avenue
Philadelphia, PA 19111
About
Director, Hematology/Oncology Fellowship Training Program
Assistant Professor, Department of Hematology/Oncology
TRDG Member, Colorectal and SI Cancer; Esophagus, Pancreas, and Liver Cancer
NCCN, Cancer-Related Fatigue Panel Member
NCCN, Older Adult Oncology Panel Member
NCCN, Pancreatic Adenocarcinoma Panel Member
Specialties
Treatment Focus
Gastrointestinal cancers; Geriatric Oncology
Research Program
Language(s) Other than English
Hebrew
Treatment Philosophy
I specialize in treatment of patients with gastrointestinal cancers with various chemotherapies. My goal is to provide each patient with cutting-age therapy for their cancer, and the supportive care necessary for tolerating treatment. I am specifically interested in caring for older adults with gastrointestinal cancers, while focusing on other factors that are not related to their cancer and complicate their care.
Follow on Twitter @efratdotan
Education, Training & Credentials
Educational Background
- Fellow & Chief Fellow, Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA
- Resident & Chief Resident, Internal Medicine, Lenox Hill Hospital, New York, NY, 2007
- Resident, Internal Medicine, Lenox Hill Hospital, New York, NY, 2006
- MD, Technion, Israel Institute of Technology, Israel, 2002
Certifications
- American Board of Internal Medicine
- Board Certification in Hematology and Medical Oncology
Memberships
- National Comprehensive Cancer Network (NCCN)
- Cancer-Related Fatigue Panel
- Occult Primary Panel
- Older Adult Oncology Panel
- American Society of Clinical Oncology (ASCO)
- International Society of Geriatric Oncology (SIOG)
- Cancer and Aging Research Group (CARG)
- Eastern Cooperative Oncology Group (ECOG)
- American Medical Association (AMA)
Honors & Awards
- AMGEN Fellowship Grant 2009;
- American College of Physician (ACP): Associate Research Competition Award
Patient Stories
Robert Evans
Robert Evans
In August 2015, Robert Evans, 70, went to a local suburban, Philadelphia hospital to have surgery for a ruptured bowl after experiencing extreme pain in his abdomen. During the surgery, doctors decided it was best to remove his appendix because it was enflamed and interfering with the procedure. This was a fairly routine procedure and a cancer diagnoses was far from Robert’s mind.
Darryl Hall
Colorectal Cancer
Darryl Hall
Colorectal Cancer
For a few months, Darryl Hall wasn’t feeling right. He was constipated and had difficulty with bowel movements. “I hadn’t been to a doctor in several years, so I decided that I should get this checked out,” recalls Darryl, 65. “My family doctor ordered both a CAT and an X-Ray and I was told a mass was detected. I was referred to a surgeon at my local hospital. After two colposcopies and anexploratory surgery, I still didn’t have answers. I would go back to see several doctors at my community hospital and the doctors never seemed to communicate. I was getting frustrated and I knew I needed to get a second opinion.”
Frances Hatalovsky
GIST (Gastrointestinal Stromal Tumor)
Frances Hatalovsky
GIST (Gastrointestinal Stromal Tumor)
When Fran Hatalovsky turned 74 in 2006, she wasn’t even entertaining the idea of retirement. In fact, when she was told by her Fox Chase Cancer Center surgeon that carcinoid cancer had spread throughout her body, her main concern was whether she'd be able to return to work. Her surgeon assured her that he would do everything in his power to make it happen. Just two months after her surgeon performed a very complex procedure to remove the cancerous tissue that affected Fran's colon, small intestine, ovaries and liver, she was able to return to work and couldn't have been more pleased.
Research Profile
Research Program
Research Interests
- Clinical trials of novel treatments for gastrointestinal cancers.
- Drug Development
- Clinical trial specific to older cancer patients
Publications
Selected Publications
Vijayvergia N, Dotan E, Devarajan K, et al. Patterns of care and outcomes of older versus younger patients with metastatic pancreatic cancer: A Fox Chase Cancer Center Experience. J Geriatr Oncol. 2015; S1879-4068. [Epub ahead of print]. PubMed
Dotan E, Li T, Hall M, Meropol N, Beck R, Wong YN. Oncologists’ Response to New Data Regarding the Use of Epidermal Growth Factor Receptor Inhibitors in Colorectal Cancer. JOP. September 2014 10(5): 308-14. PubMed
McCleary N, Dotan E, Browner I. Refining Chemotherapy Approach for Older Patients with Colon Cancer. J Clin Oncol, August 2014; 32: 2570-2580. PubMed
Dotan E, Devarajan K, D’Silva JA, Beck A, Kloth D, Cohen J S, Denlinger C. Patterns of use and tolerance of anti-epidermal growth factor receptor antibodies among older adults with metastatic colorectal cancer. Clinical Colorectal Cancer. September 2014; 13(3):192-8. PubMed
Dotan E, Meropol N, Zhu F, Bove B, Cai K, Godwin A, Golemis A, Astsaturov I, Cohen S. Increased Aurora kinase A gene copy number is associated with improved prognosis and response to chemotherapy in patients with metastatic colorectal cancer. British Journal of Cancer. 2012 Feb 14;106(4):748-55 PubMed
Dotan E, Browner I, Hurria A, Denlinger C: Challenges in the management of elderly patients with colon cancer. JNCCN February 2012, 10(2):213-24 PubMed
Dotan E, Meropol J N, Burtness B, Denlinger C et al. A phase II study of capecitabine, oxaliplatin, and cetuximab with or without bevacizumab as front line therapy for metastatic colorectal cancer. A Fox Chase Extramural Research Study. J Gastrointest Cancer, December 2012, 43(4), 562-569. PMCID: PMC340072 PubMed
Dotan E, Cohen S J. Challenges in the management of stage II colon cancer. Seminars in Oncology Aug 2011; 38(4): 511-20 PubMed
Dotan E, Cohen S J, Alpaugh K, Meropol N J. Circulating tumor cells: evolving evidence and future challenges. The oncologist, November 2009, 14(11): 1070-1082 PubMed
